Fecal Microflora in Irritable Bowel Syndrome (IBS): Characterization and Signific

描述（由申请人提供）： 肠易激综合征（IBS）的病理生理学知之甚少。流行病学[原文如此]和生理学研究表明，肠道微生物群在疾病的病理生理学中可能发挥作用。此外，由于IBS是一种异质性[原文如此]疾病，因此该病症的不同亚型可能存在不同的病因学因素;腹泻型IBS（D-IBS）、便秘型IBS（C-IBS）、混合型肠习惯IBS（M-IBS）。到目前为止，对肠道微生物群对肠道生理学和功能症状改变的贡献的理解以及关于IBS不同亚型和健康对照之间肠道微生物群差异的数据有限。我们对R 03资助的假设是，某些IBS亚型患者的肠道微生物群与健康对照组不同。拟议的研究项目将使用一种新的方法，结合三种分子生物学技术，包括末端限制性片段长度多态性（T-RFLP）指纹图谱，焦磷酸测序和定量聚合酶链反应（qPCR），以比较不同亚型IBS患者和健康对照者之间的粪便微生物群。我们将研究来自每个IBS亚组的20名患者和20名对照。这项研究的结果将被用作未来深入研究肠道微生物群在IBS中作用的初步数据。如果我们的假设得到证实，它将提供新的见解，以了解疾病，并可能导致新的机制调查和假设驱动的治疗功能性胃肠道疾病的目标是肠道植物群。这项研究的方案和结果也将为未来（NIH）的拨款申请提供基础，以进一步研究肠道细菌在这些疾病中的作用。 公共卫生相关性：肠易激综合征（IBS）是一种原因不明的胃肠道疾病，可表现为腹泻、便秘或混合性肠易激综合征（D-IBS、C-IBS和M-IBS）。最近的研究指出，我们肠道中的细菌（肠道微生物群）与这种疾病有关。这项研究的假设是，患有D-IBS，C-IBS或M-IBS的患者的肠道微生物群与健康人的微生物群不同。这项研究将使用先进的分子技术来分析患有不同亚型IBS的患者和健康人的肠道微生物群。这项研究将探讨肠道微生物群在IBS中的作用。此外，这项研究将提供深入了解IBS和我的领导新的治疗功能性胃肠道疾病。

DESCRIPTION (provided by applicant): The pathophysiology of irritable bowel syndrome (IBS) is poorly understood. Epidemology [sic] and physiological studies have suggested a possible role for the intestinal microbiota in the pathophysiology of the disorder. In addition, since IBS is a heterogenous [sic] disorder it is possible that there may be different etiological factors for the different subtypes of this condition; diarrhea-predominant IBS (D-IBS), constipation-predominant IBS (C- IBS), mixed bowel habit IBS (M-IBS). To date, the understanding of the contribution of the intestinal microbiota to the altered intestinal physiology and functional symptoms and the data regarding differences in the intestinal microbiota between the different subtypes of IBS and healthy controls are limited. Our hypothesis for this R03 grant is that the gut microbiota of patients with certain subtypes of IBS is distinct from that of healthy controls. The proposed research project will use a novel approach combining three molecular biology techniques including Terminal-Restriction Fragment Length Polymorphism (T-RFLP) fingerprinting, pyro-sequencing and quantitative polymerase chain reaction (qPCR) to compare the fecal microbiota between patients with different subtypes of IBS and healthy controls. We will study 20 patients from each IBS subgroup and 20 controls. The results of this study will be used as preliminary data for future, in depth, investigations regarding the role of the intestinal microbiota in IBS. If our hypotheses are confirmed, it will provide new insight to the understanding of the disorder and may lead to new mechanistic investigations and hypothesis driven treatments for functional GI disorders by targeting the intestinal flora. The protocols and the results from this study will also provide the basis for future (NIH) grant submissions to further investigate the role of intestinal bacteria in these disorders. PUBLIC HEALTH RELEVANCE: Irritable Bowel Syndrome (IBS) is a gastrointestinal disorder of unknown cause and can occur as diarrhea, constipation or mixed bowel habit IBS (D-IBS, C-IBS and M-IBS). Recent studies point to an association of the bacteria in our intestine (the intestinal microbiota) with this disorder. The hypothesis of this study is that the intestinal microbiota of patients experiencing D-IBS, C-IBS or M-IBS is different to the microbiota of healthy people. This study will use advanced molecular techniques to analyze the gut microbiota in patients experiencing different subtypes of IBS and healthy people. This study will investigate the role of the intestinal microbiota in IBS. Additionally, this study will provide insight to the understanding of IBS and my lead to new treatments for functional gastrointestinal disorders.